Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.78 |
| ▸ | VEGFA | P15692 | 10/20 | 0.78 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272670 | 0.91 | EGLN1 (0.88) | EGLN1VEGFAHTTLMNAPOLB | |
| SCHEMBL1774277 | 0.88 | EGLN1 (1.00) | EGLN1VEGFAHTTLMNAPOLB | |
| SCHEMBL12599456 | 0.87 | EGLN1 (0.80) | EGLN1VEGFAHTTLMNAPOLB | |
| SCHEMBL272385 | 0.84 | EGLN1 (0.76) | EGLN1VEGFAHTTKDM4ESMN1; SMN2 | |
| SCHEMBL272319 | 0.84 | VEGFA (0.75) | EGLN1VEGFAHTTLMNAMEN1 | |
| SCHEMBL12669231 | 0.79 | EGLN1 (0.72) | EGLN1VEGFAHTTKDM4ETP53 | |
| SCHEMBL278450 | 0.78 | EGLN1 (0.66) | EGLN1VEGFAHTTLMNAPOLB | |
| SCHEMBL27636549 | 0.77 | EGLN1 (0.59) | EGLN1VEGFAHTTLMNAKDM4E | |
| SCHEMBL273704 | 0.76 | EGLN1 (1.00) | EGLN1VEGFAHTTPOLBMEN1 | |
| SCHEMBL272502 | 0.76 | EGLN1 (0.71) | EGLN1VEGFAHTTPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC (US) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185778-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885VEGFA 551/4885HTT 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.